• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Pfizer Inc.

    5/19/25 4:29:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PFE alert in real time by email
    8-K
    PFIZER INC false 0000078003 0000078003 2025-05-14 2025-05-14 0000078003 us-gaap:CommonStockMember 2025-05-14 2025-05-14 0000078003 us-gaap:DeferrableNotesMember 2025-05-14 2025-05-14
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): May 14, 2025

     

     

    PFIZER INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   1-3619   13-5315170
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (I.R.S. Employer
    Identification No.)

     

    66 Hudson Boulevard East  
    New York, New York   10001-2192
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code:

    (212) 733-2323

     

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.05 par value   PFE   New York Stock Exchange
    1.000% Notes due 2027   PFE27   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     
     


    Item 8.01

    Other Events.

    On May 19, 2025, Pfizer Netherlands International Finance B.V. (the “Issuer”), a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) under Dutch law and a wholly-owned subsidiary of Pfizer Inc. (the “Company”), completed a public offering of €750,000,000 aggregate principal amount of 2.875% Notes due 2029 (the “2029 Notes”), €1,000,000,000 aggregate principal amount of 3.250% Notes due 2032 (the “2032 Notes”), €750,000,000 aggregate principal amount of 3.875% Notes due 2037 (the “2037 Notes”) and €800,000,000 aggregate principal amount of 4.250% Notes due 2045 (the “2045 Notes” and, together with the 2029 Notes, the 2032 Notes and the 2037 Notes, collectively, the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Company (collectively, the “Guarantee”).

    The offering of the Notes was made pursuant to the shelf registration statement on Form S-3 (Registration No. 333-277323) of the Company, Pfizer Investment Enterprises Pte. Ltd. and the Issuer, originally filed with the Securities and Exchange Commission (the “Commission”) on February 23, 2024, as amended by the Post-Effective Amendment No. 1 thereto, filed with the Commission on May 13, 2025.

    The Notes were issued pursuant to an indenture (the “Base Indenture”), dated as of May 19, 2025, among the Issuer, the Company and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented by the first supplemental indenture (the “First Supplemental Indenture” and, the Base Indenture as supplemented by the First Supplemental Indenture, the “Indenture”), dated as of May 19, 2025, among the Issuer, the Company and the Trustee.

    The Base Indenture and the First Supplemental Indenture are filed herewith as Exhibit 4.1 and Exhibit 4.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference. Each of the form of 2029 Notes, the form of 2032 Notes, the form of 2037 Notes and the form of 2045 Notes are filed herewith as Exhibit 4.3, Exhibit 4.4, Exhibit 4.5 and Exhibit 4.6 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

    In connection with the offering of the Notes, the Issuer and the Company entered into an underwriting agreement (the “Underwriting Agreement”) and related pricing agreement (the “Pricing Agreement”), each dated May 14, 2025, with the several underwriters listed on Schedule I to the Pricing Agreement.

    The Underwriting Agreement and the Pricing Agreement are filed herewith as Exhibit 1.1 and Exhibit 1.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

    In addition, in connection with the offering of the Notes, the Company is filing a legal opinion regarding the validity of the Notes and the Guarantee, which is filed herewith as Exhibit 5.1 to this Current Report on Form 8-K. A legal opinion of NautaDutilh N.V., relating to certain matters of Dutch law with respect to the Issuer, is also filed herewith as Exhibit 5.2 to this Current Report on Form 8-K.


    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Exhibit Description

    1.1    Underwriting Agreement, dated May 14, 2025, among Pfizer Netherlands International Finance B.V., Pfizer Inc. and the several underwriters listed on Schedule I to the Pricing Agreement.
    1.2    Pricing Agreement, dated May 14, 2025, among Pfizer Netherlands International Finance B.V., Pfizer Inc. and the several underwriters listed on Schedule I to the Pricing Agreement.
    4.1    Indenture, dated as of May 19, 2025, among Pfizer Netherlands International Finance B.V., Pfizer Inc. and The Bank of New York Mellon, as trustee.
    4.2    First Supplemental Indenture, dated as of May 19, 2025, among the Pfizer Netherlands International Finance B.V., Pfizer Inc. and The Bank of New York Mellon, as trustee.
    4.3    Form of 2.875% Notes due 2029 (included in Exhibit 4.2).
    4.4    Form of 3.250% Notes due 2032 (included in Exhibit 4.2).
    4.5    Form of 3.875% Notes due 2037 (included in Exhibit 4.2).
    4.6    Form of 4.250% Notes due 2045 (included in Exhibit 4.2).
    5.1    Opinion of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company.
    5.2    Opinion of NautaDutilh N.V.
    23.1    Consent of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company (included in Exhibit 5.1).
    23.2    Consent of NautaDutilh N.V. (included in Exhibit 5.2).
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

        PFIZER INC.

     

        By:  

    /s/ Margaret M. Madden

     

       

     

      Margaret M. Madden

     

       

     

      Senior Vice President and Corporate Secretary,

     

       

     

      Chief Governance Counsel
    Dated: May 19, 2025      
    Get the next $PFE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFE

    DatePrice TargetRatingAnalyst
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    12/10/2024$29.00Neutral
    BofA Securities
    11/15/2024$25.00Underperform
    Wolfe Research
    10/25/2024$30.00Neutral
    Citigroup
    10/17/2024$32.00Mkt Perform
    Bernstein
    8/7/2024Neutral → Outperform
    Daiwa Securities
    3/22/2024Buy → Hold
    Argus
    2/23/2024$36.00Buy
    Guggenheim
    More analyst ratings

    $PFE
    SEC Filings

    View All

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    8/11/25 5:08:12 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Pfizer Inc.

    10-Q - PFIZER INC (0000078003) (Filer)

    8/5/25 7:16:27 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PFIZER INC (0000078003) (Filer)

    8/5/25 7:08:22 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Taraporevala Cyrus

    4 - PFIZER INC (0000078003) (Issuer)

    10/2/25 4:56:13 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith James C

    4 - PFIZER INC (0000078003) (Issuer)

    10/2/25 4:56:12 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Quincey James

    4 - PFIZER INC (0000078003) (Issuer)

    10/2/25 4:55:10 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hearing Against Pfizer Set For 29 September In Contraceptive 'Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio

    The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research confirming link between use of Depo-Provera and increased risk of brain tumours Global pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection Depo-Provera (DMPA), is facing a multidistrict litigation (MDL No. 3140) in the USA being brought on behalf of women who developed an intracranial meningioma, a type of brain tumour after using Pfizer's Depo-Provera. This litigation followed a study by EPI-PHARE (Roland et al.) published in March 2024 in the British Medical Journal, which found that women who had used the Pfizer contraceptive inje

    9/25/25 3:37:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025

    More than 45 abstracts, including five late-breaking presentations and recognition in Presidential Symposium, showcase impact of approved medicines and potential of next-generation pipeline Pfizer Inc. (NYSE: PFE) will highlight data across its extensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. Data from more than 45 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 11 oral/mini oral presentations and five late-breaking sessions, will be presented across Pfizer's core scientific modalities and key tumor areas. "At ESMO, Pfizer is demonstrating how earlier in

    9/25/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

    Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

    2/26/25 9:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    12/19/23 9:31:01 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Pfizer with a new price target

    Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

    4/22/25 8:03:45 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on Pfizer with a new price target

    BofA Securities resumed coverage of Pfizer with a rating of Neutral and set a new price target of $29.00

    12/10/24 8:32:32 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Pfizer with a new price target

    Wolfe Research initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    11/15/24 8:17:04 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer

    9/23/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

    Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R&D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we're confident in our ability to cre

    8/5/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pfizer Inc. (Amendment)

    SC 13G/A - PFIZER INC (0000078003) (Subject)

    2/9/23 11:30:22 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Pfizer Inc.

    SC 13D - PFIZER INC (0000078003) (Filed by)

    7/27/22 4:42:06 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pfizer Inc. (Amendment)

    SC 13G/A - PFIZER INC (0000078003) (Subject)

    2/10/22 8:32:46 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care